Advertisement

Topics

Companies Related to "Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug" [Most Relevant Company Matches] RSS

20:12 EDT 18th October 2018 | BioPortfolio

Here are the most relevant search results for "Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug" found in our extensive corporate database of over 50,000 company records.

Showing "Study Angiocal Patients With Solid Tumors Investigating Safety" Companies 1–25 of 5,700+

Relevant

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.


Iconic Therapeutics

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...

Iconic Therapeutics, Inc.

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...


Nereus Pharmaceuticals, Inc.

Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched expertise in marine microbiology to identify unique biologically active compounds, Nereus has two oncology drug candidates in clinical trials. Plinabulin (NPI-2358), a novel vascular disrupting agent, is being evaluated in patien...

Siamab Therapeutics, Inc.

Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting cancer-specific carbohydrate antigens seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class o...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Erimos Technologies, LLC

Erimos has exclusive license for nordihydroguaiaretic acid (NDGA) derivatives from The Johns Hopkins University. We have developed a novel process to extract NDGA from the resin of the leaves of Larrea tridentata, a desert plant indigenous to the southwestern US and Mexico. EM-1421, our lead candidate, is a semi-synthetic derivative of NDGA. It is designed to target specific differences between no...

Threshold Pharmaceuticals, Inc.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effe...

Cold Genesys Inc.

Cold Genesys, Inc. is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. In 2010, Cold Genesys acquired exclusive worldwide rights to develop CG0070 from BioSante Pharmaceuticals. CG0070 is currently under investigation in a Phase II, single-arm, open-label, pivotal study (BOND II) for patient...

Gloucester Pharmaceuticals

Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through regulatory approval and commercialization. The Company’s first candidate, ISTODAX® (romidepsin), a novel histone deacetylase (HDAC) inhibitor, is FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at le...

GANYMED Pharmaceuticals AG

GANYMED Pharmaceuticals AG is developing monoclonal antibody therapeutics against solid tumors, where current therapies are poor and where there is an overriding medical need. The therapeutic efficacy of current solid cancer therapeutics is severely limited, because their molecular targets are elevated in a subset of a particular cancer but they are also found widely in normal tissues. In contrast...

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell va...

Exmovere Holdings, Inc.

Exmovere Holdings, Inc. (Frankfurt: X3M) is focused on government and consumer applications for healthcare, mobility, and security and the practical applications of the study of human emotion. The Chariot, Exmobaby pajamas, and the Telepath wristwatch are instrumental in the build out of this vision as a solid representation of Exmovere's push into enha...

WILEX AG

WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging...

WindMIL Therapeutics

When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs™) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and ...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Intensity Therapeutics is pioneering a new approach to treat cancer referred to as in situ chemovaccination. The Company creates novel, proprietary formulations of proven chemotherapy drugs. These products, w...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Immunomedics, Inc.

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled ...

Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...

Endocare

Endocare's mission is to radically improve patients lives through ground breaking core technology. Endocare promotes its cryotherapy technology to urologists for the treatment of prostate cancer and renal tumors, however, we are expanding our focus across a number of surgical markets, including the ablation of tumors in the lung and liver, as well as pain management.

Techniclone International Corporation

TECHNICLONE CORPORATION is engaged in the research and development of unique therapeutics for the treatment of cancer: The company utilizes innovative targeting technologies to develop products capable of destroying cancerous tumors throughout the body. The Company's Tumor Necrosis Therapy (TNT) is designed to deliver high doses of radiation directly to the core of the tumor while causing minimal ...

MagForce AG

MagForce AG, listed in the entry standard (MF6), together with its subsidiary MAGFORCE USA, Inc. is a leading medical device company in the field of nanomedicine in oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticl...


More From BioPortfolio on "Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks